PMID- 32318735 OWN - NLM STAT- MEDLINE DCOM- 20210809 LR - 20210809 IS - 1876-4479 (Electronic) IS - 1873-9946 (Linking) VI - 14 IP - 10 DP - 2020 Oct 5 TI - Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series. PG - 1488-1493 LID - 10.1093/ecco-jcc/jjaa078 [doi] AB - This was a multicentre case series supported by the European Crohn's and Colitis Organisation [ECCO] and performed as part of the Collaborative Network of Exceptionally Rare case reports [CONFER] project. The aim was to report on whether cutaneous lesions associated with inflammatory bowel disease [IBD] and refractory to standard medical therapy including anti-tumour necrosis factors [anti-TNFs], would respond to the newer biologic agents ustekinumab [UST] or vedolizumab [VDZ]. This report includes 28 patients with cutaneous lesions from 14 centres, all of whom had failed immunomodulator and anti-TNF therapy. Metastatic Crohn's disease [MCD] was diagnosed in 10 patients: UST led to remission in five cases and partial response in four cases, with a single report of VDZ inducing remission. All cases of MCD treated with UST responded after the first or second dose, and the median time for the five cases that attained remission was 5 months. Pyoderma gangrenosum [PG] was diagnosed in four cases: three of these attained remission with UST [median time to remission 4 months] and one case did not respond to VDZ. There were seven cases of erythema nodosum [EN]: UST led to remission in four cases and partial response in 1 case whilst VDZ had partial response in 2 cases and non-response in two cases. There were seven single cases of other inflammatory lesions. In summary, UST appears to be useful for different cutaneous lesions including MCD, PG, and EN, whereas VDZ does not appear to be useful for lesions that are independent of disease activity. CI - (c) The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn's and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Phillips, Frank M AU - Phillips FM AD - NIHR Nottingham Digestive Diseases Biomedical Research Centre, Nottingham University Hospitals, Nottingham, UK. FAU - Verstockt, Bram AU - Verstockt B AD - University Hospitals Leuven, Gastroenterology and Hepatology, KU Leuven, Chronic Diseases, Metabolism and Ageing, TARGID-IBD Unit, Leuven, Belgium. FAU - Sebastian, Shaji AU - Sebastian S AD - Hull and East Yorkshire Hospitals NHS Trust, Inflammatory Bowel Disease Unit, University of Hull and York, Hull York Medical School, Hull, UK. FAU - Ribaldone, Davide AU - Ribaldone D AD - University of Turin, Surgical Sciences, Turin, Italy. FAU - Vavricka, Stephan AU - Vavricka S AD - University Hospital Zurich, Medicine, Zurich, Switzerland. FAU - Katsanos, Konstantinos AU - Katsanos K AD - University of Ioannina School of Medical Sciences, Gastroenterology, Ioannina, Greece. FAU - Slattery, Eoin AU - Slattery E AD - University Hospital Galway, Gastroenterology, Galway, Ireland. FAU - de Suray, Nicholas AU - de Suray N AD - Grand Hopital de Charleroi, Gastroenterology and Hepatology, Charleroi, Belgium University Hospital Saint-Luc, Gastroenterology and Hepatology, Bruxelles, Belgium. FAU - Flores, Cristina AU - Flores C AD - Hospital de Clinicas de Porto Alegre, Gastroenterology, Rio Grande do Sul, Brazil. FAU - Fries, Walter AU - Fries W AD - University Messina, Clinical Unit for Chronic Bowel Disorders, Messina, Italy. FAU - Vincenzi, Francesca AU - Vincenzi F AD - University of Parma, Gastroenterology and Endoscopy Unit, Parma, Italy. FAU - Capoferro, Elvira AU - Capoferro E AD - University of Parma, Gastroenterology and Endoscopy Unit, Parma, Italy, Sacro Cuore Don Calabria of Negrar, Negrar, Italy. FAU - Bachmann, Oliver AU - Bachmann O AD - Siloah St. Trudpert Klinikum, Gastroenterology, Pforzheim, Germany. FAU - Kopylov, Uri AU - Kopylov U AD - Sheba Medical Centre, Gastroenterology, Ramat Gan, Israel. LA - eng PT - Case Reports PT - Journal Article PT - Multicenter Study PL - England TA - J Crohns Colitis JT - Journal of Crohn's & colitis JID - 101318676 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Dermatologic Agents) RN - 0 (Immunologic Factors) RN - 9RV78Q2002 (vedolizumab) RN - FU77B4U5Z0 (Ustekinumab) SB - IM MH - Adult MH - Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects MH - *Colitis, Ulcerative/complications/diagnosis/physiopathology/therapy MH - *Crohn Disease/complications/diagnosis/physiopathology/therapy MH - Dermatologic Agents/administration & dosage/adverse effects MH - Duration of Therapy MH - *Erythema Nodosum/diagnosis/drug therapy/etiology MH - Female MH - Humans MH - Immunologic Factors/administration & dosage/adverse effects MH - Male MH - Patient Acuity MH - *Pyoderma Gangrenosum/diagnosis/drug therapy/etiology MH - Remission Induction/*methods MH - Severity of Illness Index MH - *Skin Diseases/diagnosis/drug therapy/etiology MH - Treatment Outcome MH - *Ustekinumab/administration & dosage/adverse effects OTO - NOTNLM OT - Crohn's disease OT - Extraintestinal manifestations OT - metastatic Crohn's disease OT - pyoderma gangrenosum OT - ulcerative colitis EDAT- 2020/04/23 06:00 MHDA- 2021/08/10 06:00 CRDT- 2020/04/23 06:00 PHST- 2020/04/23 06:00 [pubmed] PHST- 2021/08/10 06:00 [medline] PHST- 2020/04/23 06:00 [entrez] AID - 5823596 [pii] AID - 10.1093/ecco-jcc/jjaa078 [doi] PST - ppublish SO - J Crohns Colitis. 2020 Oct 5;14(10):1488-1493. doi: 10.1093/ecco-jcc/jjaa078.